A two-part phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics.
Authors
Mitchell, Claire LO'Connor, James P B
Roberts, C
Watson, Y
Jackson, A
Cheung, S
Evans, J
Spicer, J
Harris, A
Kelly, C
Rudman, S
Middleton, M
Fielding, A
Tessier, J
Young, H
Parker, G J M
Jayson, Gordon C
Affiliation
Department of Medical Oncology, Christie Hospital NHS Trust, Withington, Manchester, UK. Claire.Mitchell@christie.nhs.ukIssue Date
2011-09
Metadata
Show full item recordAbstract
Cediranib (RECENTIN™) is an oral, highly potent VEGF inhibitor. This study evaluated the effect of food on the pharmacokinetics of cediranib and compared the administration of continual cediranib via two dosing strategies using this as a platform to investigate pharmacodynamic imaging biomarkers.Citation
A two-part phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics. 2011, 68 (3):631-41 Cancer Chemother PharmacolJournal
Cancer Chemotherapy and PharmacologyDOI
10.1007/s00280-010-1534-3PubMed ID
21120480Type
ArticleLanguage
enISSN
1432-0843ae974a485f413a2113503eed53cd6c53
10.1007/s00280-010-1534-3